Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-clotting agent does not improve outcomes of patients with severe pneumonia

23.02.2011
Use of the blood clot-inhibiting medication tifacogin does not appear to improve outcomes of patients with severe community-acquired pneumonia (sCAP), according to a study conducted by researchers from North and South America, Europe, Asia and Africa. The drug had shown some potential benefit in the sCAP subgroup of an earlier trial involving sepsis patients.

The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

"Administration of tifacogin showed no treatment benefit in this large population of patients with severe CAP,"said Richard Wunderink, MD, professor of pulmonary and critical care medicine at Northwestern University's Feinberg School of Medicine. "This result was consistent across a range of disease severity indices."

In the U.S., community-acquired pneumonia (CAP) is the eighthleading cause of death, with a death rate of 18.8/100,000. The number of individuals hospitalized with CAP annually is expected to increase up to 1 million in 2020, with similar trends in many other countries due to the disproportionate growth of the elderly population. Globally, intensive care unit mortality in patients admitted with sCAP is about 30%.

In most sCAP patients, the blood clotting system is activated as part of the response to infection, in some cases interfering with circulation and leading to multiple organ failure. Researchers hope reducing this excess clottingthrough use of anticoagulants in individuals with sCAP may prevent organ failure.

Tifacoginacts by blocking activated tissue factor, an essential for clot formation. In aprior trial of sepsis patients, tifacogin had shown some benefit for patients in that trial who had CAP. Based on those results, Dr. Wunderink said researchers involved in this study, dubbed CAPTIVATE (Community-Acquired Pneumonia Tifacogin Intra-Venous Administration Trial for Efficacy), aimed to assess the efficacy and safety of tifacogin as adjunct therapy in sCAP.

"CAP remains the most common cause of death from infection," Dr. Wunderink said. "Anti-clotting therapies are sought to complement the antimicrobial treatment and supportive care measures that are currently used for sCAP patients."

In this study, researchers enrolled 2,138 sCAPpatients from 188 centers from 2005 to 2008, randomizing them to receive tifacogin or placebo intravenously for four days. Although two doses of tifacogin (0.025 mg/kg/h and 0.075 mg/kg/h) were initially included in the study, the higher dose was dropped early on when no benefit was demonstrated.

At the end of the study although tifacogin did show an effect on clotting measures in the blood, the researchers found mortality rates and the incidence of adverse events were similar in both the tifacogin and placebo groups.

Dr. Wunderink said the study's negative results could be due to several factors.

"The coagulation and inflammatory responses may have been irreversibly activated before tifacogin was administered, or specific processes that occur during CAP may have blunted the effect of the drug," he said. "However, the most logical explanation is that tissue factor activation, while important, may not be a critical step in the pathogenesis of sCAP mortality."

Although the study showed no benefit associated with the use of tifacogin in sCAP patients, Dr. Wunderink said it clearly demonstrates the need for additional research to improve sCAP mortality rates.

"CAPTIVATE represents the largest clinical trial of severe CAP performed to date," Dr. Wunderink said. "The design and execution of the study demonstrates that a more homogeneous population with a single source ofinfection, rather than a more generic sepsis population, can be defined, which will be of benefit for future studies.

"Although theprimary end-point was not achieved, this study demonstrates the persistent unmet need forfurther interventions to improve mortality of sCAP and the feasibility of those studies," he added.

Brian Kell | EurekAlert!
Further information:
http://www.thoracic.org

More articles from Health and Medicine:

nachricht Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>